A Vutrisiran Sodium (25㎎ 0.5㎖/Syringe) 3 Syringes,Ｂ　Elapegademase (Genetical Recombination) (2.4㎎ 1.5㎖／Vial) 22 Vials,Ｃ　Atezolizumab (Genetical Recombination) (1200㎎ 20.0㎖／Vial) 35 Vials,Ｄ　Pembrolizumab (Genetical Recombination) (100.

NATIONAL UNIVERSITY CORPORATION Japan has Released a tender for A Vutrisiran Sodium (25㎎ 0.5㎖/Syringe) 3 Syringes,Ｂ　Elapegademase (Genetical Recombination) (2.4㎎ 1.5㎖／Vial) 22 Vials,Ｃ　Atezolizumab (Genetical Recombination) (1200㎎ 20.0㎖／Vial) 35 Vials,Ｄ　Pembrolizumab (Genetical Recombination) (100. in Metals and non metals. The tender was released on Mar 26, 2024.

Country - Japan

Summary - A Vutrisiran Sodium (25㎎ 0.5㎖/Syringe) 3 Syringes,Ｂ　Elapegademase (Genetical Recombination) (2.4㎎ 1.5㎖／Vial) 22 Vials,Ｃ　Atezolizumab (Genetical Recombination) (1200㎎ 20.0㎖／Vial) 35 Vials,Ｄ　Pembrolizumab (Genetical Recombination) (100.

Deadline - login to view

GT reference number - 80111202

Product classification - Sodium